Publications 2024

Qvigstad LF, Eri LM, Lien MD, Fosså SD, Aas K, Berge V (2024)
Reduction of lower urinary tract symptoms in prostate cancer patients treated with robot assisted laparoscopic prostatectomy
Scand J Urol, 59, 121-125
DOI 10.2340/sju.v59.40070, PubMed 38888041

Publications 2023

Berge V, Beisland C (2023)
[The PSA test must be used more astutely]
Tidsskr Nor Laegeforen, 143 (12)
DOI 10.4045/tidsskr.23.0528, PubMed 37668129

Møller CT, Tafjord G, Blindheim A, Berge V, Fosså S, Andreassen BK (2023)
Initial management and survival of patients with primary metastatic bladder cancer before the immunotherapy era: a population-based study from Norway
Scand J Urol, 58, 101-108
DOI 10.2340/sju.v58.5923, PubMed 37953521

Publications 2022

Guldvik IJ, Braadland PR, Sivanesan S, Ramberg H, Kristensen G, Tennstedt P, Røder A, Schlomm T, Berge V, Eri LM, Lilleby W, Mills IG, Taskén KA (2022)
Low Blood Levels of LRG1 Before Radical Prostatectomy Identify Patients with High Risk of Progression to Castration-resistant Prostate Cancer
Eur Urol Open Sci, 45, 68-75
DOI 10.1016/j.euros.2022.09.002, PubMed 36353660

Luiting HB, Remmers S, Boevé ER, Valdagni R, Chiu PK, Semjonow A, Berge V, Tully KH, Rannikko AS, Staerman F, Roobol MJ (2022)
A Multivariable Approach Using Magnetic Resonance Imaging to Avoid a Protocol-based Prostate Biopsy in Men on Active Surveillance for Prostate Cancer-Data from the International Multicenter Prospective PRIAS Study
Eur Urol Oncol, 5 (6), 651-658
DOI 10.1016/j.euo.2022.03.007, PubMed 35437217

Møller CT, Fosså SD, Tafjord G, Babigumira R, Berge V, Andreassen BK (2022)
Primary versus secondary muscle-invasive bladder cancer: survival after curative treatment
Scand J Urol, 56 (3), 214-220
DOI 10.1080/21681805.2022.2056633, PubMed 35506475

Møller CT, Støer NC, Blindheim A, Berge V, Tafjord G, Fosså SD, Andreassen BK (2022)
Downstaging and survival after Neoadjuvant chemotherapy for bladder cancer in Norway; a population-based study
BMC Cancer, 22 (1), 1301
DOI 10.1186/s12885-022-10394-w, PubMed 36510166

Ouellet V, Erickson A, GAP1 UTMAs Contributing Investigators, Wiley K, Morrissey C, Berge V, Moreno CS, Tasken KA, Trudel D, True LD, Lewis MS, Svindland A, Ertunc O, Vidal ID, Osunkoya AO, Jones T, Bova GS, Lamminen T, Achtman AH, Buzza M, Kouspou MM, Bigler SA, Zhou X, Freedland SJ, Mes-Masson AM et al. (2022)
The Movember Global Action Plan 1 (GAP1): Unique Prostate Cancer Tissue Microarray Resource
Cancer Epidemiol Biomarkers Prev, 31 (4), 715-727
DOI 10.1158/1055-9965.EPI-21-0600, PubMed 35131885

Publications 2021

Hopland OA, Fosså SD, Ottosson F, Brennhovd B, Svindland A, Hole KH, Hernes E, Eri LM, Diep LM, Berge V (2021)
Robotic salvage pelvic lymph node dissection for locoregional recurrence after radical prostatectomy: a single institution experience
Scand J Urol, 55 (4), 287-292
DOI 10.1080/21681805.2021.1946135, PubMed 34196594

Moghaddam S, Jalali A, O'Neill A, Murphy L, Gorman L, Reilly AM, Heffernan Á, Lynch T, Power R, O'Malley KJ, Taskèn KA, Berge V, Solhaug VA, Klocker H, Murphy TB, Watson RW (2021)
Integrating Serum Biomarkers into Prediction Models for Biochemical Recurrence Following Radical Prostatectomy
Cancers (Basel), 13 (16)
DOI 10.3390/cancers13164162, PubMed 34439316

Ramberg H, Richardsen E, de Souza GA, Rakaee M, Stensland ME, Braadland PR, Nygård S, Ögren O, Guldvik IJ, Berge V, Svindland A, Taskén KA, Andersen S (2021)
Proteomic analyses identify major vault protein as a prognostic biomarker for fatal prostate cancer
Carcinogenesis, 42 (5), 685-693
DOI 10.1093/carcin/bgab015, PubMed 33609362

Ramirez-Garrastacho M, Berge V, Linē A, Llorente A (2021)
Potential of miRNAs in urinary extracellular vesicles for management of active surveillance in prostate cancer patients
Br J Cancer, 126 (3), 492-501
DOI 10.1038/s41416-021-01598-1, PubMed 34811506

Thiem B, Kruszka D, Turowska N, Sliwinska E, Berge V, Kikowska M (2021)
Linnaea borealis L. var. borealis-In Vitro Cultures and Phytochemical Screening as a Dual Strategy for Its Ex Situ Conservation and a Source of Bioactive Compounds of the Rare Species
Molecules, 26 (22)
DOI 10.3390/molecules26226823, PubMed 34833914

Aas K, Berge V, Myklebust TÅ, Fosså SD (2021)
Comparative Survival Outcomes of High-risk Prostate Cancer Treated with Radical Prostatectomy or Definitive Radiotherapy Regimens
Eur Urol Open Sci, 26, 55-63
DOI 10.1016/j.euros.2021.01.011, PubMed 34337508

Publications 2020

Berge V (2020)
PENIS. A MANUAL
Tidsskr. Nor. Laegeforen., 140 (7), 710

Aas K, Dorothea Fosså S, Åge Myklebust T, Møller B, Kvåle R, Vlatkovic L, Berge V (2020)
Increased curative treatment is associated with decreased prostate cancer-specific and overall mortality in senior adults with high-risk prostate cancer; results from a national registry-based cohort study
Cancer Med, 9 (18), 6646-6657
DOI 10.1002/cam4.3297, PubMed 32750229

Publications 2019

Fosså SD, Beyer B, Dahl AA, Aas K, Eri LM, Kvan E, Falk RS, Graefen M, Huland H, Berge V (2019)
Improved patient-reported functional outcomes after nerve-sparing radical prostatectomy by using NeuroSAFE technique
Scand J Urol, 53 (6), 385-391
DOI 10.1080/21681805.2019.1693625, PubMed 31797716

Publications 2018

Braadland PR, Giskeødegård G, Sandsmark E, Bertilsson H, Euceda LR, Hansen AF, Guldvik IJ, Selnæs KM, Grytli HH, Katz B, Svindland A, Bathen TF, Eri LM, Nygård S, Berge V, Taskén KA, Tessem MB (2018)
Ex vivo metabolic fingerprinting identifies biomarkers predictive of prostate cancer recurrence following radical prostatectomy
Br J Cancer, 118 (6), e11
DOI 10.1038/bjc.2017.470, PubMed 29462127

Fan Z, Li L, Li X, Zhang M, Zhong Y, Li Y, Yu D, Cao J, Zhao J, Xiaoming Deng, Zhang M, Jian-Guo Wen, Liu Z, Goscinski MA, Berge V, Nesland JM, Suo Z (2018)
Generation of an oxoglutarate dehydrogenase knockout rat model and the effect of a high-fat diet
RSC Adv, 8 (30), 16636-16644
DOI 10.1039/c8ra00253c, PubMed 35540547

Johnson I, Ottosson F, Diep LM, Berg RE, Hoff JR, Wessel N, Eri LM, Berge V (2018)
Switching from laparoscopic radical prostatectomy to robot assisted laparoscopic prostatectomy: comparing oncological outcomes and complications
Scand J Urol, 52 (2), 116-121
DOI 10.1080/21681805.2017.1420099, PubMed 29334304

Medlow PW, Steele CJ, McCavigan AM, Reardon W, Brown CM, Lambe SM, Ishiy FAA, Walker SM, Logan GE, Raji OY, Berge V, Katz B, Kay EW, Sheehan K, Watson RW, Harkin DP, Kennedy RD, Knight LA (2018)
Analytical validation of a prognostic prostate cancer gene expression assay using formalin fixed paraffin embedded tissue
BMC Med Genomics, 11 (1), 125
DOI 10.1186/s12920-018-0442-y, PubMed 30591067

Prencipe M, Fabre A, Murphy TB, Vargyas E, O'Neill A, Bjartell A, Tasken KA, Grytli HH, Svindland A, Berge V, Eri LM, Gallagher W, Watson RW (2018)
Role of serum response factor expression in prostate cancer biochemical recurrence
Prostate, 78 (10), 724-730
DOI 10.1002/pros.23516, PubMed 29608018

Aas K, Fosså SD, Kvåle R, Møller B, Myklebust TÅ, Vlatkovic L, Müller S, Berge V (2018)
Is time from diagnosis to radical prostatectomy associated with oncological outcomes?
World J Urol, 37 (8), 1571-1580
DOI 10.1007/s00345-018-2570-6, PubMed 30483947

Publications 2017

Ahmed HU, Berge V, Bottomley D, Cross W, Heer R, Kaplan R, Leslie T, Parker C, Relton C, Stephens R, Sydes MR, Turnbull L, van der Meulen J, Vickers A, Wilt T, Emberton M, and the Prostate Cancer RCT Consensus Group (2017)
Corrigendum: Can we deliver randomized trials of focal therapy in prostate cancer?
Nat Rev Clin Oncol (in press)
DOI 10.1038/nrclinonc.2017.86, PubMed 28895571

Braadland PR, Giskeødegård G, Sandsmark E, Bertilsson H, Euceda LR, Hansen AF, Guldvik IJ, Selnæs KM, Grytli HH, Katz B, Svindland A, Bathen TF, Eri LM, Nygård S, Berge V, Taskén KA, Tessem MB (2017)
Ex vivo metabolic fingerprinting identifies biomarkers predictive of prostate cancer recurrence following radical prostatectomy
Br J Cancer, 117 (11), 1656-1664
DOI 10.1038/bjc.2017.346, PubMed 28972967

Li X, Grigalavicius M, Li Y, Li X, Zhong Y, Huang R, Yu D, Berge V, Goscinski MA, Kvalheim G, Nesland JM, Suo Z (2017)
MtDNA depletion influences the transition of CD44 subtypes in human prostate cancer DU145 cells
Tumour Biol, 39 (8), 1010428317713671
DOI 10.1177/1010428317713671, PubMed 28789597

Li X, Han G, Li X, Kan Q, Fan Z, Li Y, Ji Y, Zhao J, Zhang M, Grigalavicius M, Berge V, Goscinski MA, Nesland JM, Suo Z (2017)
Mitochondrial pyruvate carrier function determines cell stemness and metabolic reprogramming in cancer cells
Oncotarget, 8 (28), 46363-46380
DOI 10.18632/oncotarget.18199, PubMed 28624784

Li X, Lu J, Kan Q, Li X, Fan Q, Li Y, Huang R, Slipicevic A, Dong HP, Eide L, Wang J, Zhang H, Berge V, Goscinski MA, Kvalheim G, Nesland JM, Suo Z (2017)
Metabolic reprogramming is associated with flavopiridol resistance in prostate cancer DU145 cells
Sci Rep, 7 (1), 5081
DOI 10.1038/s41598-017-05086-6, PubMed 28698547

Rodríguez M, Bajo-Santos C, Hessvik NP, Lorenz S, Fromm B, Berge V, Sandvig K, Linē A, Llorente A (2017)
Identification of non-invasive miRNAs biomarkers for prostate cancer by deep sequencing analysis of urinary exosomes
Mol Cancer, 16 (1), 156
DOI 10.1186/s12943-017-0726-4, PubMed 28982366

Walker SM, Knight LA, McCavigan AM, Logan GE, Berge V, Sherif A, Pandha H, Warren AY, Davidson C, Uprichard A, Blayney JK, Price B, Jellema GL, Steele CJ, Svindland A, McDade SS, Eden CG, Foster C, Mills IG, Neal DE, Mason MD, Kay EW, Waugh DJ, Harkin DP, Watson RW et al. (2017)
Molecular Subgroup of Primary Prostate Cancer Presenting with Metastatic Biology
Eur Urol, 72 (4), 509-518
DOI 10.1016/j.eururo.2017.03.027, PubMed 28408174

Aas K, Axcrona K, Kvåle R, Møller B, Myklebust TÅ, Axcrona U, Berge V, Fosså SD (2017)
Ten-year Mortality in Men With Nonmetastatic Prostate Cancer in Norway
Urology, 110, 140-147
DOI 10.1016/j.urology.2017.07.048, PubMed 28823634

Publications 2016

Bokhorst LP, Lepistö I, Kakehi Y, Bangma CH, Pickles T, Valdagni R, Alberts AR, Semjonow A, Strölin P, Montesino MF, Berge V, Roobol MJ, Rannikko A (2016)
Complications after prostate biopsies in men on active surveillance and its effects on receiving further biopsies in the Prostate cancer Research International: Active Surveillance (PRIAS) study
BJU Int, 118 (3), 366-71
DOI 10.1111/bju.13410, PubMed 26765682

Braadland PR, Grytli HH, Ramberg H, Katz B, Kellman R, Gauthier-Landry L, Fazli L, Krobert KA, Wang W, Levy FO, Bjartell A, Berge V, Rennie PS, Mellgren G, Mælandsmo GM, Svindland A, Barbier O, Taskén KA (2016)
Low β₂-adrenergic receptor level may promote development of castration resistant prostate cancer and altered steroid metabolism
Oncotarget, 7 (2), 1878-94
DOI 10.18632/oncotarget.6479, PubMed 26646591

Moen LV, Ramberg H, Zhao S, Grytli HH, Sveen A, Berge V, Skotheim RI, Taskén KA, Skålhegg BS (2016)
Observed correlation between the expression levels of catalytic subunit, Cβ2, of cyclic adenosine monophosphate-dependent protein kinase and prostate cancer aggressiveness
Urol Oncol, 35 (3), 111.e1-111.e8
DOI 10.1016/j.urolonc.2016.10.002, PubMed 27838142

Ramberg H, Grytli HH, Nygård S, Wang W, Ögren O, Zhao S, Løvf M, Katz B, Skotheim RI, Bjartell A, Eri LM, Berge V, Svindland A, Taskén KA (2016)
PBX3 is a putative biomarker of aggressive prostate cancer
Int J Cancer, 139 (8), 1810-20
DOI 10.1002/ijc.30220, PubMed 27273830

Skotland T, Ekroos K, Kauhanen D, Simolin H, Seierstad T, Berge V, Sandvig K, Llorente A (2016)
Molecular lipid species in urinary exosomes as potential prostate cancer biomarkers
Eur J Cancer, 70, 122-132
DOI 10.1016/j.ejca.2016.10.011, PubMed 27914242

Wang L, Skotland T, Berge V, Sandvig K, Llorente A (2016)
Exosomal proteins as prostate cancer biomarkers in urine: From mass spectrometry discovery to immunoassay-based validation
Eur J Pharm Sci, 98, 80-85
DOI 10.1016/j.ejps.2016.09.023, PubMed 27664330

Publications 2015

Rud E, Baco E, Klotz D, Rennesund K, Svindland A, Berge V, Lundeby E, Wessel N, Hoff JR, Berg RE, Diep L, Eggesbø HB, Eri LM (2015)
Does preoperative magnetic resonance imaging reduce the rate of positive surgical margins at radical prostatectomy in a randomised clinical trial?
Eur Urol, 68 (3), 487-96
DOI 10.1016/j.eururo.2015.02.039, PubMed 25813692

Solberg A, Angelsen A, Berge V, Lilleby W, Iversen J, Klepp O, Brennhovd B, Johannessen D, Nygård Y, Larsen K, Stensvold A (2015)
[Re: Different guidelines for treatment of prostate cancer]
Tidsskr Nor Laegeforen, 135 (12-13), 1105
DOI 10.4045/tidsskr.15.0652, PubMed 26130530

Øverbye A, Skotland T, Koehler CJ, Thiede B, Seierstad T, Berge V, Sandvig K, Llorente A (2015)
Identification of prostate cancer biomarkers in urinary exosomes
Oncotarget, 6 (30), 30357-76
DOI 10.18632/oncotarget.4851, PubMed 26196085

Publications 2014

Ahmed HU, Berge V, Bottomley D, Cross W, Heer R, Kaplan R, Leslie T, Parker C, Relton C, Stephens R, Sydes MR, Turnbull L, van der Meulen J, Vickers A, Wilt T, Emberton M, Prostate Cancer RCT Consensus Group (2014)
Can we deliver randomized trials of focal therapy in prostate cancer?
Nat Rev Clin Oncol, 11 (8), 482-91
DOI 10.1038/nrclinonc.2014.44, PubMed 24751803

Baco E, Gelet A, Crouzet S, Rud E, Rouvière O, Tonoli-Catez H, Berge V, Chapelon JY, Eggesbø HB (2014)
Hemi salvage high-intensity focused ultrasound (HIFU) in unilateral radiorecurrent prostate cancer: a prospective two-centre study
BJU Int, 114 (4), 532-40
DOI 10.1111/bju.12545, PubMed 24930692

Dahl S, Loge JH, Berge V, Dahl AA, Cvancarova M, Fosså SD (2014)
Influence of radical prostatectomy for prostate cancer on work status and working life 3 years after surgery
J Cancer Surviv, 9 (2), 172-9
DOI 10.1007/s11764-014-0399-6, PubMed 25216609

Donaldson IA, Alonzi R, Barratt D, Barret E, Berge V, Bott S, Bottomley D, Eggener S, Ehdaie B, Emberton M, Hindley R, Leslie T, Miners A, McCartan N, Moore CM, Pinto P, Polascik TJ, Simmons L, van der Meulen J, Villers A, Willis S, Ahmed HU (2014)
Focal therapy: patients, interventions, and outcomes--a report from a consensus meeting
Eur Urol, 67 (4), 771-7
DOI 10.1016/j.eururo.2014.09.018, PubMed 25281389

Rud E, Klotz D, Rennesund K, Baco E, Berge V, Lien D, Svindland A, Lundeby E, Berg RE, Eri LM, Eggesbø HB (2014)
Detection of the index tumour and tumour volume in prostate cancer using T2-weighted and diffusion-weighted magnetic resonance imaging (MRI) alone
BJU Int, 114 (6b), E32-E42
DOI 10.1111/bju.12637, PubMed 24447606

Publications 2013

Berge V, Berg RE, Hoff JR, Wessel N, Diep LM, Karlsen SJ, Eri LM (2013)
A prospective study of transition from laparoscopic to robot-assisted radical prostatectomy: quality of life outcomes after 36-month follow-up
Urology, 81 (4), 781-6
DOI 10.1016/j.urology.2013.01.017, PubMed 23465150

Berge V, Dickinson L, McCartan N, Hindley RG, Diep LM, Emberton M, Ahmed HU (2013)
Morbidity associated with primary high intensity focused ultrasound and redo high intensity focused ultrasound for localized prostate cancer
J Urol, 191 (6), 1764-9
DOI 10.1016/j.juro.2013.12.036, PubMed 24373800

Itkonen HM, Minner S, Guldvik IJ, Sandmann MJ, Tsourlakis MC, Berge V, Svindland A, Schlomm T, Mills IG (2013)
O-GlcNAc transferase integrates metabolic pathways to regulate the stability of c-MYC in human prostate cancer cells
Cancer Res, 73 (16), 5277-87
DOI 10.1158/0008-5472.CAN-13-0549, PubMed 23720054

Publications 2011

Berge V (2011)
Editorial comment to transrectal high-intensity focused ultrasound for treatment of localized prostate cancer
Int J Urol, 18 (5), 363-4
DOI 10.1111/j.1442-2042.2011.02752.x, PubMed 21453400

Berge V, Baco E, Dahl AA, Karlsen SJ (2011)
Health-related quality of life after salvage high-intensity focused ultrasound (HIFU) treatment for locally radiorecurrent prostate cancer
Int J Urol, 18 (9), 646-51
DOI 10.1111/j.1442-2042.2011.02815.x, PubMed 21771102

Berge V, Berg RE, Hoff JR, Wessel N, Svindland A, Karlsen SJ, Eri LM (2011)
Five-year progression-free survival in 577 patients operated on with laparoscopic radical prostatectomy for localized prostate cancer
Scand J Urol Nephrol, 46 (1), 8-13
DOI 10.3109/00365599.2011.604790, PubMed 21843041

Ramberg H, Alshbib A, Berge V, Svindland A, Taskén KA (2011)
Regulation of PBX3 expression by androgen and Let-7d in prostate cancer
Mol Cancer, 10, 50
DOI 10.1186/1476-4598-10-50, PubMed 21548940

Publications 2010

Berge V, Baco E, Karlsen SJ (2010)
A prospective study of salvage high-intensity focused ultrasound for locally radiorecurrent prostate cancer: early results
Scand J Urol Nephrol, 44 (4), 223-7
DOI 10.3109/00365591003727551, PubMed 20350272

Nøkleby K, Berge V, Stiris M, Tufteland KF, Humerfelt S (2010)
[A 40ish man with weight loss and scrotum edema]
Tidsskr Nor Laegeforen, 130 (20), 2026-8
DOI 10.4045/tidsskr.09.0486, PubMed 20967042

Publications 2009

Fosså SD, Egey A, Haukaas SA, Angelsen A, Klepp O, Berge V, Axcrona K, Lilleby W (2009)
[Incorrect about hormone treatment in prostatic cancer]
Tidsskr Nor Laegeforen, 129 (5), 429
DOI 10.4045/tidsskr.08.0649, PubMed 19247406

Publications 2007

Berge V, Thompson T, Blackman D (2007)
Use of additional treatment for prostate cancer after radical prostatectomy, radiation therapy, androgen deprivation, or watchful waiting
Scand J Urol Nephrol, 41 (3), 198-203
DOI 10.1080/00365590601016677, PubMed 17469027

Publications 2006

Berge V, Thompson T, Blackman D (2006)
Additional surgical intervention after radical prostatectomy, radiation therapy, androgen-deprivation therapy, or watchful waiting
Eur Urol, 52 (4), 1036-43
DOI 10.1016/j.eururo.2006.12.012, PubMed 17178188

Publications 2005

Taskén KA, Angelsen A, Svindland A, Eide T, Berge V, Wahlquist R, Karlsen S (2005)
[Markers for diagnosis, prediction and prognosis of prostate cancer]
Tidsskr Nor Laegeforen, 125 (23), 3279-82
PubMed 16327854

Publications 2003

Thiem B, Berge V (2003)
[Cloudberry: an important source of ellagic acid, an anti-oxidant]
Tidsskr Nor Laegeforen, 123 (13-14), 1856-7
PubMed 12830265

Publications 2002

Eri LM, Wessel N, Tysland O, Berge V (2002)
Comparative study of pressure-flow parameters
Neurourol Urodyn, 21 (3), 186-93
DOI 10.1002/nau.10018, PubMed 11948710